Cover Image
Market Research Report

Sepsis - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 213120
Published Content info 320 Pages
Delivery time: 1-2 business days
Price
Back to Top
Sepsis - Pipeline Review, H1 2019
Published: April 29, 2019 Content info: 320 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2019, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 7, 1, 53, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11067IDB

Table of Contents

  • Introduction
  • Sepsis - Overview
  • Sepsis - Therapeutics Development
  • Sepsis - Therapeutics Assessment
  • Sepsis - Companies Involved in Therapeutics Development
  • Sepsis - Drug Profiles
  • Sepsis - Dormant Projects
  • Sepsis - Discontinued Products
  • Sepsis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Sepsis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Sepsis - Pipeline by Adrenomed AG, H1 2019
  • Sepsis - Pipeline by Am-Pharma BV, H1 2019
  • Sepsis - Pipeline by Arch Biopartners Inc, H1 2019
  • Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2019
  • Sepsis - Pipeline by Atox Bio Ltd, H1 2019
  • Sepsis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2019
  • Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2019
  • Sepsis - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2019
  • Sepsis - Pipeline by Cells for Cells SA, H1 2019
  • Sepsis - Pipeline by China Grand Pharmaceutical and Healthcare Holdings Ltd, H1 2019
  • Sepsis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019
  • Sepsis - Pipeline by Cilian AG, H1 2019
  • Sepsis - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by CytaCoat AB, H1 2019
  • Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2019
  • Sepsis - Pipeline by Endacea Inc, H1 2019
  • Sepsis - Pipeline by Enlivex Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by Enzychem Lifesciences Corp, H1 2019
  • Sepsis - Pipeline by Evec Inc, H1 2019
  • Sepsis - Pipeline by Immunwork Inc, H1 2019
  • Sepsis - Pipeline by InflaRx NV, H1 2019
  • Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2019
  • Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2019
  • Sepsis - Pipeline by MetrioPharm AG, H1 2019
  • Sepsis - Pipeline by Microbiotix Inc, H1 2019
  • Sepsis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Nosopharm SAS, H1 2019
  • Sepsis - Pipeline by OncoImmune Inc, H1 2019
  • Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by ProThera Biologics Inc, H1 2019
  • Sepsis - Pipeline by Q BioMed Inc, H1 2019
  • Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by Recce Ltd, H1 2019
  • Sepsis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by Ribomic Inc, H1 2019
  • Sepsis - Pipeline by Rimonyx Pharmaceuticals Ltd, H1 2019
  • Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by SetLance srl, H1 2019
  • Sepsis - Pipeline by Shionogi & Co Ltd, H1 2019
  • Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2019
  • Sepsis - Pipeline by Syntiron LLC, H1 2019
  • Sepsis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Therakind Ltd, H1 2019
  • Sepsis - Pipeline by Therashock LLC, H1 2019
  • Sepsis - Pipeline by Vascular BioSciences, H1 2019
  • Sepsis - Dormant Projects, H1 2019
  • Sepsis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Sepsis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Top 10 Routes of Administration, H1 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top